ArticleTranslational cancer research2025
Epidemiological and clinicopathologic characteristics, and prognostic factors of patients with extra-skeletal osteosarcoma: a Surveillance, Epidemiology, and End Results population study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for pulmonary metastases in osteosarcoma: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extra-skeletal osteosarcoma (ESOS) has an extremely low incidence and unclear prognosis. We studied ESOS via Surveillance, Epidemiology, and End Results data to characterize it and build a prognostic nomogram. Methods: The baseline information and survival outcome of patients were illustrated according to different primary tumor sites. The independent prognostic factors for ESOS were analyzed using univariate and multivariate Cox regression analyses. A nomogram was constructed using these prognostic factors to predict the survival of patients. The Kaplan-Meier method was performed to estimate survival, and both the log-rank test and the Wilcoxon-Breslow-Gehan test were used to compare the survival. Results: A total of 4,567 patients with osteosarcoma who met the inclusion criteria were enrolled, including 4,317 patients with osteosarcoma of bone and joint origin and 250 patients with ESOS. The 1-, 3-, and 5-year tumor-specific survival rates for ESOS were lower than those for skeletal osteosarcoma. Multivariate Cox analysis showed that older age at diagnosis, distant staging, and presence of bone metastases were independent risk factors affecting patient prognosis, and surgery of the primary site was independently associated with improved survival. A nomogram was created based on these factors to predict overall survival at 1, 3, and 5 year in patients with ESOS. An internally validated nomogram consistency index showed satisfactory results between predictions. Conclusions: Primary focus surgery is an important factor in improving survival outcomes in patients with ESOS. The nomogram for predicting the prognosis of patients with ESOS was shown to have favorable accuracy and reliability. Such a prognostic nomogram may assist clinicians in optimizing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.